Cytosorbents Q2 Loss Widens, Going Concern Warning Reiterated, Cash Dwindles to $4.4M
CTSO is trading near its 52-week low of $0.35 (14% above the low).
Summary
Cytosorbents' Q2 2026 filing reveals a $9.5M H1 net loss, a going concern warning, and only $4.4M in unrestricted cash. Nasdaq delisting risk looms as the company fails two listing standards.
Updates
· PR Newswire — Four FDA pre-submission meetings are scheduled for August 2026 to discuss the ticagrelor removal program, and the August 13 shareholder vote on a reverse stock split is pivotal to maintaining Nasdaq listing.
Key Events · Earnings and Guidance · CTSO
-
Going Concern Warning Reiterated
Management again expressed substantial doubt about the company's ability to continue as a going concern, with only $4.4 million in unrestricted cash as of June 30, 2026.
-
H1 2026 Net Loss of $9.5M
The company swung to a $9.5 million net loss in the first half of 2026 from a $0.5 million profit a year earlier, driven by foreign currency losses and higher interest expense.
-
Nasdaq Delisting Risk
Cytosorbents is non-compliant with both the $1.00 minimum bid price rule and the $35 million market value of listed securities rule, with compliance deadlines in September and December 2026.
-
FDA Delay Blocks Additional Funding
FDA approval of DrugSorb-ATR is now expected beyond 2026, meaning the company cannot access a $2.5 million loan tranche or extend its interest-only period, increasing liquidity pressure.
Analysis · CTSO · Industrial Applications And Services
Cytosorbents swung to a net loss of $9.5 million for the first half of 2026, reversing a small profit from the prior year, and once again flagged substantial doubt about its ability to continue as a going concern. Unrestricted cash dropped to $4.4 million, and the company acknowledged it fails two Nasdaq listing standards. While operating cash burn improved, the delay in FDA approval for its key product, DrugSorb-ATR, means it will not access an additional $2.5 million loan tranche or extend its interest-only period, intensifying near-term liquidity pressure. The stockholder deficit and unremediated material weaknesses in financial controls further elevate the risk profile.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 49.5% of the 190 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTSO was trading at $0.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25M. The 52-week trading range was $0.35 to $1.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.